GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » Cash Flow for Lease Financing

Denali Therapeutics (STU:4DN) Cash Flow for Lease Financing : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Cash Flow for Lease Financing?

Denali Therapeutics's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was €0.0 Mil. Denali Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2023 ), Denali Therapeutics's Cash Flow for Lease Financing remained the same in Mar. 2024 (€0.0 Mil).

Denali Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Denali Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Cash Flow for Lease Financing Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only - - - - -

Denali Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Denali Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (STU:4DN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (STU:4DN) » Definitions » Cash Flow for Lease Financing
Comparable Companies
ARWR MDGL MLTX FTRE RARE DNA CORT AXSM BHVN TRML OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
DNLI:USA
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.denalitherapeutics.com
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics (STU:4DN) Headlines

No Headlines